Tremfya® Alternatives

Tremfya, an interleukin inhibitor, is indicated for the treatment of plaque psoriasis or psoriatic arthritis in adults. Patients can learn to self-administer Tremfya subcutaneously every eight weeks, and the most common side effects are injection site reactions and an elevated risk of infection.

Tremfya is FDA approved for the following indications: Plaque Psoriasis and Psoriatic Arthritis.

Dupixent is an injectable medication that is typically administered subcutaneously every other week to treat inflammatory conditions, such as asthma and eczema, among others. Injection site reactions and eye conditions are the most frequently reported side effects. The risk of infection is low with Dupixent, unlike other biologics.

Dupixent is FDA approved for the following indications: Atopic Dermatitis, Asthma, Chronic Rhinosinusitis with Nasal Polyposis, Eosinophilic Esophagitis, Prurigo Nodularis.